{"title":"Dupilumab efficacy in relation to changes in club cell secretory protein 16.","authors":"Yui Murai, Toshiyuki Koya, Hiroki Koda, Wakana Uji, Moe Tanaka, Masahiro Endo, Kyoichiro Oshima, Takahiro Matsuda, Hiroshi Ueno, Ami Aoki, Kenjiro Shima, Yosuke Kimura, Toshiaki Kikuchi","doi":"10.1016/j.anai.2025.02.019","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although the performance of dupilumab in severe asthma has been evaluated, the detailed mechanism underlying its effect remains unclear.</p><p><strong>Objective: </strong>To analyze the effect of dupilumab on serum club cell secretory protein 16 (CC16).</p><p><strong>Methods: </strong>A total of 25 patients who were administered dupilumab and underwent computed tomography before and approximately 4 months after the introduction of dupilumab were included. Clinical and computed tomography parameters before and after dupilumab administration, such as mucus plug score and wall area measurement, were compared along with serum CC16 levels. The correlation between the clinical background and treatment effects was also evaluated.</p><p><strong>Results: </strong>The number of mucus plugs and airway wall area decreased significantly after dupilumab introduction. The number of mucus plugs was positively correlated with both age and serum IgE levels. The number of mucus plugs and airway wall area was inversely correlated with percent of predicted forced expiratory volume in 1 second (FEV<sub>1</sub>) and maximal mid-expiratory flow. Dupilumab treatment resulted in a significant increase in serum CC16 levels and led to a significant improvement in asthma symptoms, quality-of-life scores, FEV<sub>1</sub>, and exacerbation frequency. In addition, changes in CC16 were significantly correlated with changes in the fraction of exhaled nitric oxide, IgE, quality-of-life score, FEV<sub>1</sub>, maximal mid-expiratory flow, and mucus plug score.</p><p><strong>Conclusion: </strong>These data suggest that dupilumab improves symptoms and respiratory functions by altering the airway epithelial environment.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Allergy Asthma & Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.anai.2025.02.019","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Although the performance of dupilumab in severe asthma has been evaluated, the detailed mechanism underlying its effect remains unclear.
Objective: To analyze the effect of dupilumab on serum club cell secretory protein 16 (CC16).
Methods: A total of 25 patients who were administered dupilumab and underwent computed tomography before and approximately 4 months after the introduction of dupilumab were included. Clinical and computed tomography parameters before and after dupilumab administration, such as mucus plug score and wall area measurement, were compared along with serum CC16 levels. The correlation between the clinical background and treatment effects was also evaluated.
Results: The number of mucus plugs and airway wall area decreased significantly after dupilumab introduction. The number of mucus plugs was positively correlated with both age and serum IgE levels. The number of mucus plugs and airway wall area was inversely correlated with percent of predicted forced expiratory volume in 1 second (FEV1) and maximal mid-expiratory flow. Dupilumab treatment resulted in a significant increase in serum CC16 levels and led to a significant improvement in asthma symptoms, quality-of-life scores, FEV1, and exacerbation frequency. In addition, changes in CC16 were significantly correlated with changes in the fraction of exhaled nitric oxide, IgE, quality-of-life score, FEV1, maximal mid-expiratory flow, and mucus plug score.
Conclusion: These data suggest that dupilumab improves symptoms and respiratory functions by altering the airway epithelial environment.
期刊介绍：
Annals of Allergy, Asthma & Immunology is a scholarly medical journal published monthly by the American College of Allergy, Asthma & Immunology. The purpose of Annals is to serve as an objective evidence-based forum for the allergy/immunology specialist to keep up to date on current clinical science (both research and practice-based) in the fields of allergy, asthma, and immunology. The emphasis of the journal will be to provide clinical and research information that is readily applicable to both the clinician and the researcher. Each issue of the Annals shall also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
